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Background
Neuro-inflammation has been implicated in the progres-
sion of both acute and chronic neurological diseases.
Resident cells of the central nervous system (CNS) detect
soluble amyloid-b (Ab) through the toll-like receptors
(TLRs), involving Myd88 and interferon regulatory factor
(IRF) signalling, and triggers pro-inflammatory cytokine
release. Type-1 interferons (IFNs) are master regulators of
the pro-inflammatory cytokine response, however, their
CNS function remains largely unclear. Type-1 IFNs bind
their cognate receptor IFNAR1, activating the JAK-STAT
signalling pathway. Significantly, this cascade has been
implicated as a mediator soluble Ab1-42-induced toxicity
[1]. We have previously demonstrated that removal of
IFNAR1, contributes to neuro-protection following Ab1-
42 insult, decreasing type-1 IFN production and apoptosis.
This study investigated a role for type-1 IFNs in an AD
mouse model and utilised an in vitro approach to analyse
TLR signalling as a potential production pathway.
Materials and methods
Total protein brain extracts were prepared from wild-
type and B6C3-TgAPPswe, PSEN1ΔE9 (APP/PS1) mice
(9 months) with IFNa levels measured by ELISA and
phosphorylated Stat-3 (p-Stat-3) by Western blot.
Immunohistochemistry was performed on aged brains
(13 months) using p-Stat-3, FOX-3a and GFAP antibodies.
Primary wild-type and Myd88-/- murine neurons were
treated with 2.5µM Ab1-42 for 24-72 hours and Q-PCR
analysed IFNa, IFNb, IL-1b and IL-6 expression. BE(2)-
M17 human neuroblastoma cells were transfected stably
with an IRF7 or transiently with an IRF3 knockdown (KD)
shRNA plasmid or negative control (NC) plasmid and
subjected to 7.5µM Ab1-42 for 24-96 hours. Q-PCR
analysed IFNa and IFNb expression, Western blot deter-
mined p-Stat-3 expression, and an MTS assay assessed
cell viability.
Results
APP/PS1 brains (9 months) demonstrated a significant
2-fold increase in IFNa protein levels compared to aged
matched controls (n=4, P<0.05). Western blot analysis
confirmed robust p-Stat-3 in these APP/PS1 brains
(n=4). Immunohistochemistry of 13 month brains con-
firmed co-localisation of p-Stat-3 with the neuronal
marker, FOX-3a, not the glial marker, GFAP (n=5).
Following Ab1-42 treatment Myd88-/- neurons showed
reduced IFNa (5.3-fold), IFNb (2.2-fold), IL-1b (2.1-
fold) and IL-6 (27.2-fold) expression (n=2, 24hrs). IRF7
KD in M17 cells did not alter the Ab1-42-induced type-1
IFN response with no change in Ab1-42 toxicity compared
to NC cells (n=3). However, M17 IRF3 KD cells demon-
strated reduced IFNa (3.7-fold) and IFNb (2.3-fold)
expression following Ab1-42 insult (n=3, P<0.05, 24hrs).
This correlated with reduced Ab-induced toxicity com-
pared to NC cells (97.7% vs. 65.2%, 96hrs, n=5, P<0.05).
Conclusions
This study supports a role for type-1 IFN signalling in
the pro-inflammatory response generated by Ab. The
data suggests that Ab-induced type-1 IFN production is
TLR-regulated and occurs through an IRF3-dependent
mechanism. Modulating these pathways may be beneficial
in reducing type-1 IFN production and neuro-inflammation,
consequently limiting neuronal damage in AD.
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